TheraRadar
Data updated: May 26, 2026

IBANDRONATE SODIUM

Musculoskeletal Approved 2012-03-19

Ibandronate sodium helps postmenopausal women manage bone health by treating and preventing osteoporosis. It works to increase bone mineral density, which helps reduce the occurrence of vertebral fractures. Because the ideal length of treatment is not yet known, healthcare providers should regularly re-evaluate whether a patient needs to continue therapy, particularly after three to five years of use.

Source: FDA Label • Apotex

How IBANDRONATE SODIUM Works

This medication works by binding to hydroxyapatite in the bone matrix to inhibit osteoclast activity and reduce bone turnover. By slowing the rate of bone resorption, it helps postmenopausal women achieve a net gain in bone mass.

12
Indications
--
Phase 3 Trials
14
Years on Market

IBANDRONATE SODIUM Approval History

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
73 FDA actions from 2012 to 2026
Feb 2026 SUPPL
Label · Labeling
Aug 2025 SUPPL
Label · Labeling
Jul 2025 SUPPL
Label · Labeling

What IBANDRONATE SODIUM Treats

1 indications

IBANDRONATE SODIUM is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Osteoporosis
Source: FDA Label

IBANDRONATE SODIUM Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to IBANDRONATE SODIUM

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

ACTIVELLA
ESTRADIOL
1 shared
Novo Nordisk
Shared indications:
ATELVIA
RISEDRONATE SODIUM
1 shared
APIL
Shared indications:
BILDYOS
DENOSUMAB-NXXP
1 shared
SHANGHAI HENLIUS BIOTECH
Shared indications:
📋

Clinical Trial Registry

1 trials
Trial Sponsor ID Phase Status Title
NCT01627886 BA0859144-01 Ph 1 completed Bioequivalence Study of Ibandronate Sodium Tablets 150 mg Under Fasting Condition
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

IBANDRONATE SODIUM FDA Label Details

Indications & Usage

FDA Label (PDF)

IBANDRONATE SODIUM is indicated for the treatment of Osteoporosis.

Looking for the branded version?

BONIVA

Full clinical data, patents, trials, and competitive landscape for ibandronate sodium.

See BONIVA

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.